Enabled Therapeutics

Enabled Therapeutics is pioneering a revolutionary approach to CNS drug development with our pathology-gated therapeutic activation technology for small molecules. For decades, treatments for brain diseases have failed because of insurmountable barriers: 🧠 Crossing the blood-brain barrier Achieving therapeutic levels in the brain Precision treatment avoiding side effects in healthy tissue We have a solution for them all! Our breakthrough small-molecule technology remains inactive in healthy brain regions and activates only where pathology exists. This allows us to target Alzheimer’s, epilepsy, ALS, glioblastoma, and other devastating conditions with unprecedented precision. Backed by robust data and led by the proven team behind Raptor Pharmaceuticals (acquired in 2016), Enabled Therapeutics is advancing toward the clinic in the next 12–18 months. With one platform, we open the door to dozens of previously “undruggable” CNS targets — a true CRISPR moment for neurology. This is not incremental progress. This is a revolution. invest@enabledtherapeutics.com